Liminatus Pharma, Inc. (LIMN) - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Liminatus Pharma, Inc. on August 3, 2026. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Fullerton, CA. The filing details the voting results for three proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Shareholders representing approximately 48.31% of outstanding shares (32,446,373 shares) participated in the meeting. All three proposals were approved:
- Election of Directors: Stockholders elected Nicholas Fernandez and Dr. Ji Yeon Baek as Class I directors. Both nominees received over 23.3 million votes "For" with approximately 229,000 to 230,000 votes "Against."
- Ratification of Auditors: Withum Smith+Brown PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 31,489,701 votes "For" and 893,511 votes "Against."
- Reverse Stock Split and Charter Amendment: Stockholders authorized the Board to implement a reverse stock split of up to 1-for-50 shares to meet Nasdaq listing requirements. The proposal received 30,123,230 votes "For" and 2,305,303 votes "Against."
Guidance, Outlook, and Risks
The primary strategic objective identified in the filing is to maintain the company's listing on The Nasdaq Stock Market. The approved reverse stock split is intended to address minimum bid price and other quantitative listing requirements. No specific financial guidance or management commentary regarding future operational outlook was included in this specific filing.
Investor Verification Checklist
- Verify the specific reverse stock split ratio (up to 1-for-50) that the Board of Directors ultimately selects and the effective date.
- Confirm the company's current compliance status with Nasdaq minimum bid price requirements.
- Review the definitive proxy statement (Schedule 14A filed July 13, 2026) for detailed biographies of the newly elected directors and the full rationale for the auditor ratification.
- Monitor subsequent filings for the implementation of the charter amendment reflecting the reverse stock split.